JP2015524423A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524423A5 JP2015524423A5 JP2015523573A JP2015523573A JP2015524423A5 JP 2015524423 A5 JP2015524423 A5 JP 2015524423A5 JP 2015523573 A JP2015523573 A JP 2015523573A JP 2015523573 A JP2015523573 A JP 2015523573A JP 2015524423 A5 JP2015524423 A5 JP 2015524423A5
- Authority
- JP
- Japan
- Prior art keywords
- chemical substance
- treatment
- medicament
- chemical
- cognitive impairment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000126 substance Substances 0.000 claims 53
- 208000014644 Brain disease Diseases 0.000 claims 24
- 208000010877 cognitive disease Diseases 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 22
- 208000028698 Cognitive impairment Diseases 0.000 claims 20
- 239000000203 mixture Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000000843 powder Substances 0.000 claims 7
- JKVNJTYHRABHIY-WXVUKLJWSA-N [(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-yl] benzoate Chemical group O([C@H]1C=C[C@]23CCN(C)CC4=CC=C(C(O[C@H]2C1)=C43)OC)C(=O)C1=CC=CC=C1 JKVNJTYHRABHIY-WXVUKLJWSA-N 0.000 claims 5
- 229940126321 benzgalantamine Drugs 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 5
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims 4
- 229940050410 gluconate Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- CVHZOJJKTDOEJC-UHFFFAOYSA-M 1,1-dioxo-1,2-benzothiazol-3-olate Chemical compound C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-M 0.000 claims 3
- 206010033799 Paralysis Diseases 0.000 claims 3
- 125000001931 aliphatic group Chemical group 0.000 claims 3
- 238000012377 drug delivery Methods 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 239000007921 spray Substances 0.000 claims 3
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical class C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 230000002980 postoperative effect Effects 0.000 claims 2
- 230000001953 sensory effect Effects 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- 206010003497 Asphyxia Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical group C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 108090000371 Esterases Proteins 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical class C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 208000029033 Spinal Cord disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical class C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 206010001584 alcohol abuse Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 239000010419 fine particle Substances 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims 1
- 150000002790 naphthalenes Chemical class 0.000 claims 1
- 239000007922 nasal spray Substances 0.000 claims 1
- 229940097496 nasal spray Drugs 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 239000003176 neuroleptic agent Substances 0.000 claims 1
- 230000000701 neuroleptic effect Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 235000018343 nutrient deficiency Nutrition 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 229930192474 thiophene Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 0 COc1c2OC(CC(C=C3)OC(*)=O)C3(CCN(*)C3)c2c3cc1 Chemical compound COc1c2OC(CC(C=C3)OC(*)=O)C3(CCN(*)C3)c2c3cc1 0.000 description 3
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261676348P | 2012-07-27 | 2012-07-27 | |
| EP12178187 | 2012-07-27 | ||
| US61/676,348 | 2012-07-27 | ||
| EP12178187.6 | 2012-07-27 | ||
| PCT/EP2013/065880 WO2014016430A1 (en) | 2012-07-27 | 2013-07-29 | Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018000060A Division JP6574002B2 (ja) | 2012-07-27 | 2018-01-04 | 選ばれた処方物によるガランタミンの向上した脳バイオアベイラビリティおよび親油性プロドラッグの経粘膜投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015524423A JP2015524423A (ja) | 2015-08-24 |
| JP2015524423A5 true JP2015524423A5 (OSRAM) | 2016-09-29 |
| JP6272857B2 JP6272857B2 (ja) | 2018-01-31 |
Family
ID=49996636
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015523573A Expired - Fee Related JP6272857B2 (ja) | 2012-07-27 | 2013-07-29 | 選ばれた処方物によるガランタミンの向上した脳バイオアベイラビリティおよび親油性プロドラッグの経粘膜投与 |
| JP2018000060A Expired - Fee Related JP6574002B2 (ja) | 2012-07-27 | 2018-01-04 | 選ばれた処方物によるガランタミンの向上した脳バイオアベイラビリティおよび親油性プロドラッグの経粘膜投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018000060A Expired - Fee Related JP6574002B2 (ja) | 2012-07-27 | 2018-01-04 | 選ばれた処方物によるガランタミンの向上した脳バイオアベイラビリティおよび親油性プロドラッグの経粘膜投与 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150190401A1 (OSRAM) |
| EP (2) | EP3417862B1 (OSRAM) |
| JP (2) | JP6272857B2 (OSRAM) |
| CN (2) | CN104507461A (OSRAM) |
| AU (1) | AU2013294917B2 (OSRAM) |
| CA (1) | CA2878135C (OSRAM) |
| DK (2) | DK2877165T3 (OSRAM) |
| ES (1) | ES2700473T3 (OSRAM) |
| HK (1) | HK1206242A1 (OSRAM) |
| IN (1) | IN2015DN00229A (OSRAM) |
| PL (2) | PL3417862T3 (OSRAM) |
| WO (1) | WO2014016430A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090253654A1 (en) | 2005-09-22 | 2009-10-08 | Galantos Pharma Gmbh | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
| PT3417862T (pt) * | 2012-07-27 | 2021-08-06 | Neurodyn Life Sciences Inc | Biodisponibilidade cerebral da galantamina melhorada através de formulações selecionadas e administração transmucosal de pró-fármacos lipofílicos |
| US11219627B2 (en) | 2014-05-16 | 2022-01-11 | Synaptec Development Llc | Clearance of amyloid beta |
| JP2020033304A (ja) * | 2018-08-30 | 2020-03-05 | 医療法人ふじいやさか | 薬剤又はサプリメント、組成物、及び水素供給器の使用 |
| CN114828848A (zh) * | 2019-06-28 | 2022-07-29 | 宾夕法尼亚大学理事会 | 用于治疗阿尔茨海默氏病的鼻内丹曲林施用 |
| EP4029867A1 (en) * | 2021-01-13 | 2022-07-20 | Alpha Cognition Inc. | Solid forms of galantamine benzoate gluconate |
| AU2021445637A1 (en) * | 2021-05-14 | 2023-11-23 | Alpha Cognition Inc. | Self-preserving compositions and multi-use dispensers for administering alpha-1062 |
| EP4186509A1 (en) | 2021-11-26 | 2023-05-31 | Alpha Cognition Inc. | Alpha-1062 for treating traumatic brain injury |
| EP4436575A4 (en) * | 2021-11-26 | 2025-11-19 | Alpha Cognition Inc | ALPHA-1062 INTENDED FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY |
| WO2024239120A1 (en) * | 2023-05-25 | 2024-11-28 | Alpha Cognition Inc. | Benzgalantamine for treating persistent post-concussion symptoms |
| US12208167B1 (en) * | 2024-02-06 | 2025-01-28 | Alpha Cognition Inc. | Coated tablets for pH-dependent release of benzgalantamine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1248059B (it) * | 1991-06-14 | 1995-01-05 | Miat Spa | Insufflatore multidose per farmaci in polvere |
| SK1912004A3 (en) * | 2001-10-31 | 2004-09-08 | Pfizer Prod Inc | Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome |
| US20040254146A1 (en) * | 2002-05-21 | 2004-12-16 | Nastech Pharmaceutical Company Inc. | Carboxylate salts of galantamine and their pharmaceutical use |
| DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
| JP2009508903A (ja) * | 2005-09-22 | 2009-03-05 | ガラントス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 認知障害を伴う疾患の治療に用いるための脳血液関門透過性が改善されたコリン作用増強剤 |
| US20090253654A1 (en) * | 2005-09-22 | 2009-10-08 | Galantos Pharma Gmbh | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
| US9808509B2 (en) * | 2007-06-08 | 2017-11-07 | Healthpartners Research Foundation | Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system |
| JP2009197874A (ja) * | 2008-02-20 | 2009-09-03 | Works Bell:Kk | 動力伝達装置 |
| CA2721007C (en) * | 2008-04-14 | 2014-04-29 | Galantos Pharma Gmbh | Derivatives of galantamine as pro-drugs for the treatment of human brain diseases |
| US20130317117A1 (en) * | 2010-11-24 | 2013-11-28 | Pharmaceutics International, Inc. | Self micro-emulsifying drug delivery system with increased bioavailability |
-
2013
- 2013-07-29 EP EP18186075.0A patent/EP3417862B1/en active Active
- 2013-07-29 WO PCT/EP2013/065880 patent/WO2014016430A1/en not_active Ceased
- 2013-07-29 DK DK13745810.5T patent/DK2877165T3/da active
- 2013-07-29 AU AU2013294917A patent/AU2013294917B2/en active Active
- 2013-07-29 CN CN201380039870.3A patent/CN104507461A/zh active Pending
- 2013-07-29 JP JP2015523573A patent/JP6272857B2/ja not_active Expired - Fee Related
- 2013-07-29 US US14/417,502 patent/US20150190401A1/en not_active Abandoned
- 2013-07-29 HK HK15106777.9A patent/HK1206242A1/xx unknown
- 2013-07-29 CA CA2878135A patent/CA2878135C/en active Active
- 2013-07-29 PL PL18186075T patent/PL3417862T3/pl unknown
- 2013-07-29 PL PL13745810T patent/PL2877165T3/pl unknown
- 2013-07-29 DK DK18186075.0T patent/DK3417862T3/da active
- 2013-07-29 CN CN201810140325.8A patent/CN108245522A/zh active Pending
- 2013-07-29 EP EP13745810.5A patent/EP2877165B1/en active Active
- 2013-07-29 ES ES13745810T patent/ES2700473T3/es active Active
-
2015
- 2015-01-09 IN IN229DEN2015 patent/IN2015DN00229A/en unknown
-
2018
- 2018-01-04 JP JP2018000060A patent/JP6574002B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015524423A5 (OSRAM) | ||
| JP2013545730A5 (OSRAM) | ||
| JP6896015B2 (ja) | 注射速度が増大したアリピプラゾール調合物 | |
| JP2014517050A5 (OSRAM) | ||
| JP2017509684A5 (OSRAM) | ||
| JP2011503044A5 (OSRAM) | ||
| JP2013526544A5 (OSRAM) | ||
| FI3766876T3 (fi) | Kinolonijohdannaista sisältävä farmaseuttinen formulaatio | |
| JP2000256194A (ja) | 核内レセプタ作動薬およびその効果増強剤 | |
| JP2011500781A5 (OSRAM) | ||
| US20180185404A1 (en) | Compositions and methods for the treatment of viral infection | |
| RS65144B1 (sr) | Postupak za lečenje prader-vilijevog sindroma | |
| JP2016505050A5 (OSRAM) | ||
| WO2023155837A1 (zh) | 具有镇痛和/或止痒功能的药物组合物及其用途 | |
| JP2017536410A5 (OSRAM) | ||
| US10555917B1 (en) | Methods of treating a neurological or psychiatric disorder | |
| DE60203106T2 (de) | Azolylcarbynol-derivative von aryl (oder heteroaryl) zur behandlung von atemwegserkrankungen | |
| JP7062804B2 (ja) | レビー小体病の治療および／または予防剤 | |
| CN104546705B (zh) | 一种五味子酚的药物新用途及其均质混悬剂的制备方法 | |
| JP2015524460A5 (OSRAM) | ||
| EP3270923B1 (en) | Therapeutic agent for frontal lobe dysfunction | |
| ATE453392T1 (de) | Imidazolcarbonsäurealkylester-haltiges medikament zur behandlung neurodegenerativer erkrankungen | |
| JP2021525796A (ja) | 神経疾患の阻害 | |
| JPH0840903A (ja) | 抗癌剤により誘発される末梢神経障害を予防するための医薬組成物 | |
| WO2022122040A1 (zh) | 白果内酯或银杏内酯组合物在制备镇静药物中的应用 |